αααααβααΎαONC β’ NASDAQ
add
BeOne Medicines AG
329.88$
18 ααΈα αΆ, 9:53:29 AM ααααβααα -4 · USD · NASDAQ · ααα
ααααΈαααααΆααα·αααα½ααα»αααααΌα
ααΆαβα αα»αααΌααααααααααΆαα
α»ααααααΈαα
α’αΆαααα·α
αα·αααΈαα»α
321.36$
α
αααααααααααα
321.18$ - 330.43$
α
ααααααα½αααααΆαα
α»αααααα
172.67$ - 330.43$
ααΎαβαα»αβααΈααααΆα
38.73Β αααΈααΆα USD
ααα ααα½αααΌαααααα
425.80Β ααΆαα
α’αα»ααΆα P/E
-
αα·αααααβααΆαααΆα
-
αααα»αβααααααΆαβ
α α·ααααααααα»
αααΆαααΆαααααααΆααα
αααΌα
α
αααΌα
α
αααΌααα»ααα
| (USD) | αα·αα»ααΆ 2025info | ααΆαααααΆααααααΌαααΆαβααααΆα |
|---|---|---|
α
αααΌα | 1.32Β αααΈααΆα | 41.56% |
α
αααΆαααααα·ααααα·ααΆα | 537.91Β ααΆα | 21.23% |
α
αααΌααα»ααα | 94.32Β ααΆα | 178.34% |
ααααΆααα
αααααα»ααα | 7.17 | 155.32% |
βα
αααΌααα»αααβαααα»ααα½αααΆαα αα»α | 0.84 | 173.04% |
α
αααΌααα»ααααα»αααΆαααααΆαα αααα ααΆαααααα αα·αααΆαααΆααααααα | 117.75Β ααΆα | 241.18% |
α’ααααΆαααααααααΆαααααα·αααααΆα | 5.25% | β |
αααααΈαααα»ααα
ααααααααα»α
ααΆαααα½ααα»αααααΌαααα»α
| (USD) | αα·αα»ααΆ 2025info | ααΆαααααΆααααααΌαααΆαβααααΆα |
|---|---|---|
ααΆα
αααααΆαα αα·αααΆααα·αα·αααααααααααααΈ | 2.76Β αααΈααΆα | 6.30% |
ααααααααα»α | 6.30Β αααΈααΆα | 10.26% |
ααΆαααα½ααα»αααααΌαααα»α | 2.53Β αααΈααΆα | 7.76% |
ααΌαβααααα»α | 3.77Β αααΈααΆα | β |
ααΆαα αα»αβαα·αβααΆααααΆαααα | 110.03Β ααΆα | β |
ααααααααααΉαααααα
| 9.36 | β |
ααα
ααααααΎαααααα | 3.62% | β |
ααα
ααααααΎααΎααα»α | 4.73% | β |
ααα αΌαβααΆα
αβααααΆααβ
ααΆααααααααα½αβααΆα
αααααΆαααα»ααα
| (USD) | αα·αα»ααΆ 2025info | ααΆαααααΆααααααΌαααΆαβααααΆα |
|---|---|---|
α
αααΌααα»ααα | 94.32Β ααΆα | 178.34% |
ααΆα
αααααΆααααΈααααα·ααααα·ααΆα | 263.60Β ααΆα | 375.76% |
ααΆα
αααααΆααααΈααΆααα·αα·ααα | -66.60Β ααΆα | 40.01% |
ααΆα
αααααΆααααΈα α·ααααβαααααΆα | 35.02Β ααΆα | 52.17% |
ααΆααααααααα½αβααΆα
αααααΆαααα»ααα | 255.50Β ααΆα | 234.82% |
ααα αΌαααΆα
αααααΆααααααα | 180.43Β ααΆα | 247.61% |
α’αααΈ
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024 the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
ααΆααααααΎαα‘αΎα
28 αα»ααΆ 2010
αααααβαααααΆα
αα»ααααα·α
11,000
